RNTX — Rein Therapeutics Balance Sheet
0.000.00%
- $28.43m
- $67.72m
Annual balance sheet for Rein Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 13.8 | 45.9 | 21.2 | 17.3 | 12.9 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 16.3 | 48.2 | 21.9 | 18.3 | 13.7 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.015 | 0.28 | 0.11 | 0.019 | 0.001 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 16.3 | 48.5 | 22 | 106 | 62.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 3.96 | 4.51 | 3.38 | 4.38 | 5.75 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.18 | 4.58 | 3.38 | 7.71 | 7.8 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 12.2 | 43.9 | 18.6 | 98.3 | 54.4 |
| Total Liabilities & Shareholders' Equity | 16.3 | 48.5 | 22 | 106 | 62.2 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |